LIB Therapeutics announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA ...
Coronary heart disease (CHD) is a leading cause of morbidity and mortality globally. Hypercholesterolemia is one of the major risk factors for CHD. With the increase in aging populations and ...
Familial hypercholesterolemia results from gene mutations approximately halving the number of functional LDL receptors in heterozygotes and a greater lack in homozygotes. Reduced receptor-mediated ...
February is Heart Health Month, a time dedicated to raising awareness about cardiovascular health and the risks associated ...
A new study published in Archives of Gerontology and Geriatrics Plus found that 10% of South Asian immigrants aged 45 and ...
Higher LDL cholesterol levels (≥130 mg/dL) were linked to longer survival in Sardinian nonagenarians, challenging the ...
A new study published this week in Archives of Gerontology and Geriatrics Plus found that 10% of South Asian immigrants aged ...
Deadly grip of cardiovascular diseases on Filipino families MANILA, Philippines—Heart attacks and strokes are among the most ...
MANILA – Heart attacks and strokes are among the most well-known medical conditions in the Philippines, yet they remain the country’s leading causes of death. Year after year, they claim countless ...
SHANGHAI, China I5, 2025 I YolTech Therapeutics, a clinical-stage in vivo gene editing company committed to pioneering the next generation of ...
Esperion Therapeutics has two approved LDL-C lowering therapies, Nexletol and Nexlizet, but lacks a strong pipeline for future growth.